Breast cancer remains the most prevalent malignancy among women globally, manifesting a wide spectrum of clinical outcomes. Early-stage, localized breast cancer typically boasts favorable prognoses, yet the advent of metastatic dissemination drastically diminishes survival prospects. While factors such as cancer subtype and hormone receptor status have long been recognized for their prognostic value, emerging evidence emphasizes the critical role of intercellular communication within the tumor microenvironment. This complex cellular crosstalk enables cancer cells to manipulate their surroundings, facilitating metastatic spread and resistance to conventional therapies.

Central to this communication network is the protein Jagged1, previously identified as highly expressed in aggressive, hormone receptor-negative breast cancers. However, the specific functional contributions of Jagged1 in breast cancer progression had remained elusive until now. In their novel investigation, doctoral researcher Marjaana Parikainen and colleagues demonstrate that Jagged1 not only exacerbates tumor growth but also accelerates metastasis, correlating with poorer survival in patients afflicted with aggressive breast cancer phenotypes.

Employing a comprehensive array of cancer models enriched by clinical breast cancer patient data, the research team uncovered an uncharted mode of cellular dialogue between malignant breast cells and fibroblasts mediated by Jagged1. Fibroblasts, the architects of the extracellular matrix (ECM), play a fundamental role in maintaining tissue architecture and regulating cellular behavior through the ECM’s structural components and signaling molecules. The study reveals that the presence of Jagged1 on breast cancer cells spurs adjacent fibroblasts into an activated state that elevates the production of collagen and remodels the ECM to favor tumor progression.

This Jagged1-induced fibroblast activation leads to pronounced structural alterations in the ECM, notably the alignment of collagen fibers into linear tracks. These aligned fibers act as conduits, facilitating directional migration of cancer cells and thereby enhancing their metastatic potential. Such matrix remodeling significantly influences tissue stiffness — a biomechanical property long recognized to impact cancer cell behavior and therapy response.

Delving deeper into the molecular cascade, the researchers illuminated a critical link between Jagged1 expression and the activation of the transforming growth factor beta (TGFβ) signaling pathway. TGFβ is an established master regulator implicated in late-stage breast cancer progression, known for promoting fibrosis, elevating matrix stiffness, and fostering metastatic dissemination. Their findings reveal that Jagged1 amplifies TGFβ activity, leading to intensified collagen deposition and ECM linearization, thereby creating a microenvironment conducive to cancer cell invasion.

Remarkably, the study also uncovers a self-perpetuating feedback loop where increased matrix stiffness further upregulates Jagged1 expression on cancer cells. This mechanosensitive response, coupled with TGFβ’s known role in inducing Jagged1, establishes a vicious cycle that continuously drives tumor aggression and remodeling. Consequently, the tumor microenvironment evolves dynamically, reinforcing malignant phenotypes and fostering therapeutic resistance.

The implications of these insights are profound, not only deepening our understanding of the tumor-stroma interplay but also highlighting Jagged1 as a promising therapeutic target. Interrupting this feedback mechanism could disrupt the pro-tumorigenic remodeling of the ECM, impeding metastasis and potentially enhancing the efficacy of existing treatments for triple-negative and hormone receptor-negative breast cancers, which currently pose significant clinical challenges.

Collaboration with Professor Jyrki Heino’s research group at the University of Turku fortified the multidisciplinary approach of this investigation, combining expertise in cell biology, extracellular matrix biochemistry, and oncology. Funding support from prominent Finnish foundations and the Research Council of Finland underscores the national commitment to combating breast cancer through innovative research.

Published in the high-impact journal Science Advances on March 18, 2026, this study marks a significant advance in cancer biology. It underscores the necessity of targeting not only cancer cells but also their microenvironmental communication networks and biomechanical context to achieve comprehensive cancer control.

Looking forward, the elucidation of Jagged1’s role invites further exploration into the development of inhibitors or modulators that can selectively target this molecular interaction axis. Such targeted therapies could revolutionize management strategies for aggressive breast cancer forms, aligning with the broader aims of personalized medicine.

The InFLAMES Research Flagship’s integrative approach exemplifies the power of combining immunological and molecular research to unlock novel diagnostic and therapeutic pathways. As more is uncovered about tumor microenvironment dynamics, it becomes increasingly evident that multi-faceted intervention strategies will be key to overcoming cancer metastasis and resistance.

For further information, inquiries can be directed to doctoral researcher Marjaana Parikainen or Professor Cecilia Sahlgren at Åbo Akademi University, whose contact details are available to facilitate academic collaborations and media engagement.

Subject of Research: Cells

Article Title: Jagged1 regulates extracellular matrix deposition and remodeling in triple-negative breast cancer

News Publication Date: 18-Mar-2026

Web References: 10.1126/sciadv.aea9562

Keywords: Breast Cancer, Jagged1, Tumor Microenvironment, Extracellular Matrix, Fibroblasts, TGFβ Pathway, Metastasis, Matrix Remodeling, Cancer Progression, Triple-Negative Breast Cancer, Tumor Stiffness, Cell–Cell Communication

The current battle against breast cancer continuously faces challenges owing to tumor heterogeneity and resistance to conventional therapies. Researchers Pellegrino, M., Occhiuzzi, M.A., Marra, M., and colleagues have rigorously analyzed Silodosin’s effect on breast cancer cell lines, revealing a complex interplay at the molecular level that impairs cancer cell survival and proliferation. Their work, published in Cell Death Discovery, combines advanced molecular biology techniques and bioinformatics to elucidate the underlying mechanisms by which Silodosin exerts its anti-neoplastic effects.

Central to the study is the identification of Silodosin’s ability to modulate adrenergic signaling pathways within breast cancer cells. Traditionally, Silodosin acts as an alpha-1 adrenergic receptor antagonist, primarily providing symptomatic relief by relaxing smooth muscles in the prostate and bladder neck. However, the research team discovered that these alpha-1 receptors are also expressed aberrantly in certain breast cancer subtypes. Silodosin’s binding to these receptors disrupts downstream signaling cascades, notably those involved in cellular proliferation and survival.

Through an extensive analysis involving gene expression profiling coupled with protein quantification via western blotting, the researchers demonstrated a marked downregulation of key oncogenic pathways. Notably, Silodosin treatment led to attenuation in the PI3K/AKT/mTOR axis, a pathway notoriously associated with tumor growth, metabolism, and resistance to apoptosis. This molecular interference resulted in a significant reduction in proliferation rates, as confirmed by cellular assays including BrdU incorporation and colony formation tests.

Further investigations revealed that Silodosin induces a pronounced apoptotic response in breast cancer cells. This programmed cell death is mediated through both intrinsic and extrinsic pathways, demonstrated by increased activation of caspase enzymes and mitochondrial membrane depolarization. The release of cytochrome c and subsequent activation of caspase-9 align with intrinsic apoptosis induction, while the upregulation of death receptors such as Fas suggests engagement of extrinsic mechanisms. These findings collectively depict Silodosin as a dual-action agent capable of overriding cancer cell survival defenses.

Beyond apoptosis, Silodosin also exerts anti-metastatic effects by influencing epithelial-to-mesenchymal transition (EMT), a process critical for cancer invasion and metastasis. The study documented a decrease in mesenchymal markers like vimentin and N-cadherin, alongside an elevation of epithelial marker E-cadherin, indicating a reversal of EMT. This phenotypic reprogramming was corroborated by functional assays showing diminished migratory and invasive capabilities, suggesting Silodosin’s potential to hinder metastatic dissemination in vivo.

The researchers further evaluated Silodosin’s impact on the tumor microenvironment. Conditioned media experiments and co-culture systems indicated that Silodosin modulates the secretory profile of cancer-associated fibroblasts (CAFs), reducing pro-tumorigenic cytokines such as TGF-beta and IL-6. This alteration hampers the crosstalk between stromal and cancer cells, thereby disrupting a supportive niche typically fostering tumor progression and chemoresistance.

Significantly, the repurposing strategy offers practical advantages in clinical translation. Given Silodosin’s established safety profile, pharmacokinetics, and FDA approval for urological indications, repositioning this drug for breast cancer therapy could expedite the pathway to clinical trials. This strategy circumvents the prolonged and costly process usually associated with de novo drug development, providing a faster, resource-efficient alternative to address unmet oncologic needs.

The study also emphasized the importance of patient stratification in future clinical applications. Breast cancer subtypes expressing elevated levels of alpha-1 adrenergic receptors or demonstrating hyperactivation of implicated signaling pathways may benefit most from Silodosin therapy. Hence, biomarker-driven approaches would be critical to optimize therapeutic outcomes and minimize adverse effects.

In terms of combination therapies, preliminary synergy assessments suggested that Silodosin enhances the efficacy of commonly used chemotherapeutic agents like doxorubicin and paclitaxel. The drug appears to sensitize breast cancer cells to these agents by modulating survival pathways and promoting apoptotic susceptibility. This finding paves the way for incorporating Silodosin into multi-modal treatment regimens, potentially improving response rates and reducing required chemotherapy dosages.

From a molecular modeling perspective, the study utilized in silico docking analyses to affirm Silodosin’s binding affinity and specificity to alpha-1 adrenergic receptor isoforms expressed in breast cancer cells. These computational insights not only validate experimental findings but also provide a platform for designing novel analogs with enhanced anti-cancer properties.

The translational potential of these findings was supported by in vivo validation in murine xenograft models, where Silodosin administration significantly impeded tumor growth without eliciting notable toxicity. Tumors from treated animals showed increased apoptotic markers and reduced angiogenesis, mirroring in vitro observations and reinforcing the drug’s therapeutic promise.

In sum, this multidisciplinary investigation elucidates Silodosin’s multifaceted anti-cancer activities at the molecular, cellular, and organism levels. The repurposing of Silodosin signifies a paradigm shift, leveraging known pharmacodynamics to innovate breast cancer therapy. As research advances, integrating such repositioned drugs in precision oncology could revolutionize treatment paradigms, offering hope for improved survival and quality of life for patients worldwide.

Given the escalating urgency for novel breast cancer treatments, the identification of Silodosin’s anti-cancer effects represents a timely and impactful scientific milestone. Future clinical trials and mechanistic studies will be pivotal in translating these insights into efficacious therapies, underscoring the power of molecular research in the fight against cancer.

Subject of Research: Anti-cancer effects and molecular mechanisms of Silodosin in breast cancer treatment

Article Title: Molecular insights into Silodosin’s anti-cancer effects: a promising repurposing strategy for breast cancer

Article References:
Pellegrino, M., Occhiuzzi, M.A., Marra, M. et al. Molecular insights into Silodosin’s anti-cancer effects: a promising repurposing strategy for breast cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-02973-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-02973-8